HALIX BV

Executive Summary

HALIX BV is a privately held, fully licensed end-to-end biologics Contract Development and Manufacturing Organization (CDMO) headquartered in Leiden, Netherlands, within the renowned Leiden Bio Science Park. Founded in 2012, the company specializes in the development and GMP manufacturing of viral vectors (including vaccines) and recombinant proteins for both clinical and commercial stages. With a state-of-the-art, fully-owned facility, HALIX serves as a strategic partner for biotech and pharmaceutical companies seeking outsourced manufacturing solutions in the rapidly growing gene therapy and vaccine markets. The company's position in the European CDMO landscape is strengthened by increasing demand for viral vector production capacity, particularly for gene therapies and mRNA-based vaccines. While specific financials are not disclosed, HALIX's focused expertise and operational infrastructure position it well to capture market share in the biologics outsourcing space. The executive summary reflects a conviction in the company's niche specialization and growth potential within the CDMO sector.

Upcoming Catalysts (preview)

• Q4 2026Expansion of viral vector manufacturing capacity80% success
• H2 2026Major client partnership or contract win for commercial-stage production60% success
• Q1 2027Regulatory approval or certification for new manufacturing capabilities (e.g., mRNA or cell therapy)50% success